

Louis B Nabors

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/443248/publications.pdf>

Version: 2024-02-01

171
papers

11,924
citations

28274

55
h-index

28297

105
g-index

175
all docs

175
docs citations

175
times ranked

14231
citing authors

#	ARTICLE	IF	CITATIONS
1	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1100-1108.	10.7	800
2	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385.	10.7	776
3	Human cytomegalovirus infection and expression in human malignant glioma. <i>Cancer Research</i> , 2002, 62, 3347-50.	0.9	518
4	Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3212-3218.	1.6	489
5	Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme. <i>Journal of Clinical Oncology</i> , 2008, 26, 5610-5617.	1.6	448
6	A Phase I Open-Label, Dose-Escalation, Multi-Institutional Trial of Injection with an E1B-Attenuated Adenovirus, ONYX-015, into the Peritumoral Region of Recurrent Malignant Gliomas, in the Adjuvant Setting. <i>Molecular Therapy</i> , 2004, 10, 958-966.	8.2	401
7	Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States. <i>Clinical Cancer Research</i> , 2010, 16, 2443-2449.	7.0	392
8	Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. <i>Journal of Clinical Investigation</i> , 2001, 108, 1657-1665.	8.2	386
9	Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBM. <i>Molecular Therapy</i> , 2009, 17, 199-207.	8.2	346
10	Phase I and Correlative Biology Study of Cilengitide in Patients With Recurrent Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2007, 25, 1651-1657.	1.6	276
11	A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses. <i>Molecular Therapy</i> , 2014, 22, 1048-1055.	8.2	233
12	SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma. <i>Science Translational Medicine</i> , 2015, 7, 289ra86.	12.4	207
13	Treatment of Relapsed Central Nervous System Lymphoma with High-Dose Methotrexate. <i>Clinical Cancer Research</i> , 2004, 10, 5643-5646.	7.0	196
14	Phase I Single-Dose Study of Intracavitary-Administered Iodine-131-TM-601 in Adults With Recurrent High-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2006, 24, 3644-3650.	1.6	194
15	Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. <i>Neuro-Oncology</i> , 2015, 17, 708-717.	1.2	191
16	Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1225-1235.	4.1	174
17	Loss of Protein Inhibitors of Activated STAT-3 Expression in Glioblastoma Multiforme Tumors: Implications for STAT-3 Activation and Gene Expression. <i>Clinical Cancer Research</i> , 2008, 14, 4694-4704.	7.0	163
18	NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1331-1345.	4.9	160

#	ARTICLE	IF	CITATIONS
19	Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 731-739.	1.6	159
20	The RNA-Binding Protein HuR Promotes Glioma Growth and Treatment Resistance. <i>Molecular Cancer Research</i> , 2011, 9, 648-659.	3.4	132
21	Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma. <i>Cancer Research</i> , 2018, 78, 3002-3013.	0.9	122
22	Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. <i>Human Gene Therapy Clinical Development</i> , 2016, 27, 69-78.	3.1	113
23	A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). <i>Cancer</i> , 2012, 118, 5601-5607.	4.1	112
24	A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma. <i>Clinical Cancer Research</i> , 2013, 19, 900-908.	7.0	112
25	Quantitative immunocytochemistry using an image analyzer. I. Hardware evaluation, image processing, and data analysis. <i>Journal of Neuroscience Methods</i> , 1988, 26, 1-23.	2.5	111
26	Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2014, 17, 430-9.	1.2	108
27	Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1209-1217.	2.3	108
28	Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. <i>Neuro-Oncology</i> , 2017, 19, 1119-1126.	1.2	107
29	Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR. <i>Cancer Research</i> , 2003, 63, 4181-7.	0.9	105
30	The ELAV RNA-stability factor HuR binds the 5'-untranslated region of the human IGF-1R transcript and differentially represses cap-dependent and IRES-mediated translation. <i>Nucleic Acids Research</i> , 2005, 33, 2962-2979.	14.5	104
31	Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 1586-1594.	7.0	103
32	Medical decision-making capacity in patients with malignant glioma. <i>Neurology</i> , 2009, 73, 2086-2092.	1.1	101
33	The ING4 Tumor Suppressor Attenuates NF- κ B Activity at the Promoters of Target Genes. <i>Molecular and Cellular Biology</i> , 2008, 28, 6632-6645.	2.3	100
34	Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11. <i>Neuro-Oncology</i> , 2004, 6, 21-27.	1.2	98
35	Cilengitide: an RGD pentapeptide α 3 and α 5 integrin inhibitor in development for glioblastoma and other malignancies. <i>Future Oncology</i> , 2011, 7, 339-354.	2.4	98
36	Lyn Kinase Activity Is the Predominant Cellular Src Kinase Activity in Glioblastoma Tumor Cells. <i>Cancer Research</i> , 2005, 65, 5535-5543.	0.9	97

#	ARTICLE	IF	CITATIONS
37	<i>MGMT</i> Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. <i>Clinical Cancer Research</i> , 2019, 25, 1809-1816.	7.0	94
38	IL-1 γ induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3' untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIAR. <i>International Journal of Cancer</i> , 2005, 113, 911-919.	5.1	93
39	Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: Results of North Central Cancer Treatment Group protocol N0177. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1192-1199.	0.8	88
40	Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with <i>EGFR</i> -amplified, recurrent glioblastoma: results from an international phase I multicenter trial. <i>Neuro-Oncology</i> , 2019, 21, 106-114.	1.2	84
41	Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro. <i>Journal of Neuro-Oncology</i> , 2014, 118, 61-72.	2.9	82
42	Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: Quality and analysis results of a phase I trial. <i>Journal of Magnetic Resonance Imaging</i> , 2004, 20, 913-922.	3.4	80
43	Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2011, 55, 77-81.	1.8	80
44	Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy. <i>Nature Communications</i> , 2020, 11, 4660.	12.8	80
45	NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. <i>Neuro-Oncology</i> , 2013, 15, 490-496.	1.2	79
46	Cancer susceptibility variants and the risk of adult glioma in a US case-control study. <i>Journal of Neuro-Oncology</i> , 2011, 104, 535-542.	2.9	77
47	Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2010, 100, 95-103.	2.9	73
48	Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. <i>Journal of Clinical Investigation</i> , 2001, 108, 1657-1665.	8.2	72
49	Distress and quality of life in primary high-grade brain tumor patients. <i>Supportive Care in Cancer</i> , 2009, 17, 793-799.	2.2	71
50	Characterization and immunotherapeutic potential of β 2-microglobulin T-cells in patients with glioblastoma. <i>Neuro-Oncology</i> , 2009, 11, 357-367.	1.2	69
51	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2022, 28, 594-602.	7.0	67
52	Implementation and utilization of the molecular tumor board to guide precision medicine. <i>Oncotarget</i> , 2017, 8, 57845-57854.	1.8	67
53	A functional polymorphism in the pre-miR-146a gene is associated with risk and prognosis in adult glioma. <i>Journal of Neuro-Oncology</i> , 2011, 105, 639-646.	2.9	66
54	Hu Antigen Specificities of ANNA-I Autoantibodies in Paraneoplastic Neurological Disease. <i>Journal of Autoimmunity</i> , 1999, 13, 435-443.	6.5	65

#	ARTICLE	IF	CITATIONS
55	Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. <i>Oncotarget</i> , 2016, 7, 15018-15032.	1.8	62
56	Circadian pathway genes in relation to glioma risk and outcome. <i>Cancer Causes and Control</i> , 2014, 25, 25-32.	1.8	57
57	Ipilimumab-Induced Encephalopathy with a Reversible Splenic Lesion. <i>Cancer Immunology Research</i> , 2015, 3, 598-601.	3.4	57
58	ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2009-2009.	1.6	56
59	Amyotrophic Lateral Sclerosis-linked Mutant SOD1 Sequesters Hu Antigen R (HuR) and TIA-1-related Protein (TIAR). <i>Journal of Biological Chemistry</i> , 2009, 284, 33989-33998.	3.4	55
60	A Phase 1 Trial of ABT-510 Concurrent With Standard Chemoradiation for Patients With Newly Diagnosed Glioblastoma. <i>Archives of Neurology</i> , 2010, 67, 313-9.	4.5	53
61	Increased Expression of Thymidylate Synthetase (TS), Ubiquitin Specific Protease 10 (USP10) and Survivin is Associated with Poor Survival in Glioblastoma Multiforme (GBM). <i>Journal of Neuro-Oncology</i> , 2006, 80, 261-274.	2.9	51
62	Cognition in patients with newly diagnosed brain metastasis: profiles and implications. <i>Journal of Neuro-Oncology</i> , 2014, 120, 179-185.	2.9	51
63	An Update on Neurofibromatosis Type 1-Associated Gliomas. <i>Cancers</i> , 2020, 12, 114.	3.7	50
64	The role of Src family kinases in growth and migration of glioma stem cells. <i>International Journal of Oncology</i> , 2014, 45, 302-310.	3.3	49
65	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. <i>Neuro-Oncology</i> , 2019, 21, 1498-1508.	1.2	49
66	Reproductive factors and risk of primary brain tumors in women. <i>Journal of Neuro-Oncology</i> , 2014, 118, 297-304.	2.9	47
67	Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGHT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	46
68	High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRI. <i>Magnetic Resonance in Medicine</i> , 2009, 61, 615-625.	3.0	45
69	Phosphoregulation of the RNA-binding Protein Hu Antigen R (HuR) by Cdk5 Affects Centrosome Function. <i>Journal of Biological Chemistry</i> , 2012, 287, 32277-32287.	3.4	45
70	Quantitative immunocytochemistry using an image analyzer. II. Concentration standards for transmitter immunocytochemistry. <i>Journal of Neuroscience Methods</i> , 1988, 26, 25-34.	2.5	43
71	Hu antigen R (HuR) multimerization contributes to glioma disease progression. <i>Journal of Biological Chemistry</i> , 2017, 292, 16999-17010.	3.4	43
72	Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cells. <i>Cancer Biology and Therapy</i> , 2019, 20, 979-988.	3.4	43

#	ARTICLE	IF	CITATIONS
73	Rare TP53 genetic variant associated with glioma risk and outcome. <i>Journal of Medical Genetics</i> , 2012, 49, 420-421.	3.2	42
74	Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. <i>Neuro-Oncology</i> , 2011, 13, 1324-1330.	1.2	39
75	Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. <i>Neuro-Oncology</i> , 2017, 19, 845-852.	1.2	39
76	An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome. <i>Cancer Causes and Control</i> , 2012, 23, 1443-1449.	1.8	38
77	Anthropometric factors in relation to risk of glioma. <i>Cancer Causes and Control</i> , 2013, 24, 1025-1031.	1.8	38
78	HuR, a novel target of anti-Hu antibodies, is expressed in non-neural tissues. <i>Journal of Neuroimmunology</i> , 1998, 92, 152-159.	2.3	37
79	Isolated Central Nervous System Posttransplant Lymphoproliferative Disorder Treated with High-Dose Intravenous Methotrexate. <i>American Journal of Transplantation</i> , 2009, 9, 1243-1248.	4.7	36
80	Capacity to Consent to Research Participation in Adults With Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2010, 28, 3844-3850.	1.6	35
81	Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. <i>Neuro-Oncology</i> , 2008, 10, 608-616.	1.2	32
82	Prediagnostic body weight and survival in high grade glioma. <i>Journal of Neuro-Oncology</i> , 2013, 114, 79-84.	2.9	30
83	Rationally Designed Pharmacogenomic Treatment Using Concurrent Capecitabine and Radiotherapy for Glioblastoma; Gene Expression Profiles Associated with Outcome. <i>Clinical Cancer Research</i> , 2010, 16, 2890-2898.	7.0	29
84	Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 1139-45.	4.1	29
85	Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?. <i>Journal of Neuro-Oncology</i> , 2018, 138, 163-171.	2.9	28
86	Repeatability of ¹⁸ F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 393-398.	5.0	27
87	1p/19q chromosome deletions in metastatic oligodendroglioma. <i>Journal of Neuro-Oncology</i> , 2006, 80, 203-207.	2.9	25
88	Complementary therapy and survival in glioblastoma. <i>Neuro-Oncology Practice</i> , 2015, 2, 122-126.	1.6	25
89	Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071 and CORE Trials. <i>Clinical Cancer Research</i> , 2022, 28, 129-136.	7.0	25
90	Capacity of patients with brain metastases to make treatment decisions. <i>Psycho-Oncology</i> , 2015, 24, 1448-1455.	2.3	24

#	ARTICLE	IF	CITATIONS
91	<i>SSBP2</i> Variants Are Associated with Survival in Glioblastoma Patients. <i>Clinical Cancer Research</i> , 2012, 18, 3154-3162.	7.0	23
92	Mutant tristetraprolin: a potent inhibitor of malignant glioma cell growth. <i>Journal of Neuro-Oncology</i> , 2013, 113, 195-205.	2.9	23
93	Impairment of medical decisional capacity in relation to Karnofsky Performance Status in adults with malignant brain tumor. <i>Neuro-Oncology Practice</i> , 2015, 2, 13-19.	1.6	23
94	Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics. <i>International Journal of Cancer</i> , 2020, 146, 739-748.	5.1	23
95	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. <i>Neuro-Oncology</i> , 2020, 22, 601-612.	1.2	23
96	Brain tumor risk according to germ-line variation in the <i>MLLT10</i> locus. <i>European Journal of Human Genetics</i> , 2015, 23, 132-134.	2.8	22
97	Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery. <i>Neuro-Oncology</i> , 2020, 22, 1422-1424.	1.2	22
98	Role of MRI in Primary Brain Tumor Evaluation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1561-1568.	4.9	20
99	IMCT-08ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015, 17, v109.1-v109.	1.2	20
100	The use of cannabidiol for seizure management in patients with brain tumor-related epilepsy. <i>Neurocase</i> , 2017, 23, 287-291.	0.6	20
101	Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. <i>Neurosurgery</i> , 2019, 85, E607-E608.	1.1	20
102	Blocking PD1/PDL1 Interactions Together with MLN4924 Therapy is a Potential Strategy for Glioma Treatment. <i>Journal of Cancer Science & Therapy</i> , 2018, 10, 190-197.	1.7	19
103	Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors. <i>Cancer Research</i> , 2021, 81, 2220-2233.	0.9	19
104	Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2011, 105, 375-381.	2.9	18
105	Primary central nervous system angiosarcoma: two case reports. <i>Journal of Medical Case Reports</i> , 2012, 6, 251.	0.8	18
106	Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters. <i>Journal of Neuro-Oncology</i> , 2014, 120, 361-370.	2.9	18
107	Analysis of the 5' end of the mouse <i>Elavl1</i> (mHuA) gene reveals a transcriptional regulatory element and evidence for conserved genomic organization. <i>Gene</i> , 2000, 242, 125-131.	2.2	17
108	ELAVL1 Role in Cell Fusion and Tunneling Membrane Nanotube Formations with Implication to Treat Glioma Heterogeneity. <i>Cancers</i> , 2020, 12, 3069.	3.7	17

#	ARTICLE	IF	CITATIONS
109	Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent pediatric patients. <i>Pediatric Blood and Cancer</i> , 2010, 55, 1227-1230.	1.5	16
110	Treatment of adults with recurrent malignant glioma. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 509-514.	2.8	15
111	Growth Factor Dependent Regulation of Centrosome Function and Genomic Instability by HuR. <i>Biomolecules</i> , 2015, 5, 263-281.	4.0	14
112	Individualized screening trial of innovative glioblastoma therapy (INSIGHt).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS2079-TPS2079.	1.6	14
113	Safety and activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrent glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2027-2027.	1.6	14
114	The versatile role of HuR in Glioblastoma and its potential as a therapeutic target for a multi-pronged attack. <i>Advanced Drug Delivery Reviews</i> , 2022, 181, 114082.	13.7	14
115	Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: the University of Alabama at Birmingham experience. <i>Neuro-Oncology Practice</i> , 2014, 1, 172-177.	1.6	13
116	Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 3186-3192.	1.6	13
117	Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study. <i>PLoS Medicine</i> , 2019, 16, e1002810.	8.4	13
118	Sex hormone-dependent attenuation of EAE in a transgenic mouse with astrocytic expression of the RNA regulator HuR. <i>Journal of Neuroimmunology</i> , 2012, 246, 34-37.	2.3	12
119	Early life exposures and the risk of adult glioma. <i>European Journal of Epidemiology</i> , 2013, 28, 753-758.	5.7	12
120	SWI/SNF gene variants and glioma risk and outcome. <i>Cancer Epidemiology</i> , 2013, 37, 162-165.	1.9	12
121	Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2015, 122, 585-593.	2.9	12
122	Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 73-79.	7.0	12
123	Cognitive Predictors of Reasoning through Treatment Decisions in Patients with Newly Diagnosed Brain Metastases. <i>Journal of the International Neuropsychological Society</i> , 2015, 21, 412-418.	1.8	11
124	Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. <i>European Journal of Cancer</i> , 2018, 101, 95-104.	2.8	11
125	Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2058-2058.	1.6	11
126	<sc>SRI</sc>â€42127, a novel small molecule inhibitor of the <sc>RNA</sc> regulator <sc>HuR</sc>, potently attenuates glial activation in a model of lipopolysaccharideâ€induced neuroinflammation. <i>Glia</i> , 2022, 70, 155-172.	4.9	10

#	ARTICLE	IF	CITATIONS
127	Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM.. Journal of Clinical Oncology, 2019, 37, 2017-2017.	1.6	10
128	Analgesic use and the risk of primary adult brain tumor. European Journal of Epidemiology, 2016, 31, 917-925.	5.7	9
129	Methylmercury exposure, genetic variation in metabolic enzymes, and the risk of glioma. Scientific Reports, 2019, 9, 10861.	3.3	9
130	An early feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma: first cohort in US. CNS Oncology, 2019, 8, CNS30.	3.0	9
131	Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial.. Journal of Clinical Oncology, 2017, 35, 2003-2003.	1.6	9
132	Toenail iron, genetic determinants of iron status, and the risk of glioma. Cancer Causes and Control, 2013, 24, 2051-2058.	1.8	8
133	Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas. Journal of Neuro-Oncology, 2015, 125, 123-131.	2.9	8
134	Primary Sellar Rhabdomyosarcoma Arising in Association With a Pituitary Adenoma. International Journal of Surgical Pathology, 2016, 24, 753-756.	0.8	6
135	ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM. Neuro-Oncology, 2018, 20, vi13-vi14.	1.2	6
136	Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).. Journal of Clinical Oncology, 2016, 34, 2542-2542.	1.6	5
137	A novel technique to quantify glioma tumor invasion using serial microscopy sections. Journal of Neuroscience Methods, 2006, 153, 183-189.	2.5	4
138	Complications from pharmacotherapy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 235-250.	1.8	4
139	Older age at the completion of linear growth is associated with an increased risk of adult glioma. Cancer Causes and Control, 2017, 28, 709-716.	1.8	4
140	ACTR-15. SAFETY AND PRELIMINARY ACTIVITY OF PT2385, A FIRST-IN-CLASS HIF2-ALPHA INHIBITOR, PLANNED INTERIM ANALYSIS OF AN OPEN LABEL, SINGLE-ARM PHASE II STUDY IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi14-vi14.	1.2	3
141	Phase 1/2 trial of bevacizumab plus TPI 287, a brain penetrable anti-microtubule agent, in patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2016, 34, 2055-2055.	1.6	3
142	Catheter placement selection for convection-enhanced delivery of therapeutic agents to brain tumors. F1000Research, 0, 9, 1415.	1.6	3
143	Magnetic Resonance Cisternography in the Diagnosis of Delayed Iatrogenic Cerebrospinal Fistula: A Case Report. Journal of Neuroimaging, 1997, 7, 244-247.	2.0	2
144	The Role of Bevacizumab in Glioblastoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1201-1202.	4.9	2

#	ARTICLE	IF	CITATIONS
145	Reply to F. Felix et al and M.F. Fay et al. Journal of Clinical Oncology, 2016, 34, 3107-3108.	1.6	2
146	Data Matching to Support Analysis of Cancer Epidemiology Among Veterans Compared With Non-Veteran Populations—An Exemplar in Brain Tumors. JCO Clinical Cancer Informatics, 2021, 5, 985-994.	2.1	2
147	Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM.. Journal of Clinical Oncology, 2017, 35, 2005-2005.	1.6	2
148	Management of Central Nervous System Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 579-582.	4.9	2
149	Mitochondrial DNA sequence variation and risk of glioma. Mitochondrion, 2022, 63, 32-36.	3.4	2
150	Pilot Study to Explore the Accuracy of Current Prediction Equations in Assessing Energy Needs of Patients with Newly Diagnosed Glioblastoma Multiforme. Nutrition and Cancer, 2016, 68, 926-934.	2.0	1
151	ACTR-18. PHASE II TRIAL OF TEMOZOLOMIDE AND TRC 102, BASE EXCISION REPAIR INHIBITOR, IN BEVACIZUMAB NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE. Neuro-Oncology, 2018, 20, vi15-vi15.	1.2	1
152	A troublesome burden, the amplification of EGFR in glioblastoma!. Neuro-Oncology, 2020, 22, 594-595.	1.2	1
153	Final results from the dose-escalation stage of a phase 1/2 trial of TPI 287, a brain penetrable microtubule inhibitor, plus bevacizumab in patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2017, 35, 2021-2021.	1.6	1
154	Abstract CT314: Interim results from a phase I/II trial of TPI 287, a novel brain penetrable antimicrotubule agent, in combination with bevacizumab for the treatment of recurrent glioblastoma. Cancer Research, 2015, 75, CT314-CT314.	0.9	1
155	ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2003-2003.	1.6	1
156	Abstract 2262: Chemotherapy, checkpoint inhibition, and MGMT-modified adoptive gamma-delta ($\gamma\delta$) T cell-based therapy to treat post-resection, primary glioblastomas. , 2019, , .		1
157	Mitochondrial DNA sequence variation and risk of meningioma. Journal of Neuro-Oncology, 2021, 155, 319-324.	2.9	1
158	Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. Neuro-Oncology Advances, 2022, 4, vdab186.	0.7	1
159	Sellar Sarcoma Arising in Association With a Pituitary Adenoma. American Journal of Clinical Pathology, 2015, 144, A011-A011.	0.7	0
160	When less is better: care of the elderly with glioblastoma. Neuro-Oncology, 2017, 19, 879-879.	1.2	0
161	ATIM-21. UPDATED RESULTS OF A PHASE I TRIAL OF ANTI-LAG-3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM. Neuro-Oncology, 2018, 20, vi5-vi5.	1.2	0
162	NIMG-13. SEGMENTATION AND VOLUMETRIC ANALYSIS IMPROVES DETECTION OF PROGRESSION IN LOW GRADE GLIOMAS. Neuro-Oncology, 2018, 20, vi178-vi178.	1.2	0

#	ARTICLE	IF	CITATIONS
163	ACTR-20. A SMALL MOLECULE AXL INHIBITOR, BGB324 " FIRST-IN-HUMAN GBM SURGICAL PK TRIAL FOR RECURRENT TUMORS. Neuro-Oncology, 2018, 20, vi15-vi15.	1.2	0
164	Highlights of the inaugural ten " the launch of Neuro-Oncology Advances. Neuro-Oncology Advances, 2019, 1, vdz016.	0.7	0
165	Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics. Neuro-Oncology, 2020, 22, 1713-1714.	1.2	0
166	Digital measurement of functional status of patients with glioblastoma.. Journal of Clinical Oncology, 2021, 39, 2016-2016.	1.6	0
167	Abstract 877: Genetic variation in podoplanin in relation to glioma risk and outcome. , 2011, , .		0
168	Timed-sequential therapy with mibefradil and temozolomide in patients with recurrent high-grade gliomas: A phase I Adult Brain Tumor Consortium study.. Journal of Clinical Oncology, 2015, 33, 2033-2033.	1.6	0
169	Abstract 233: Evaluating glioma risk associated with extent of European admixture in African-Americans and Latinos. , 2018, , .		0
170	Abstract 3335: Characterization and analysis of the complement immune system in glioblastoma (GBM). , 2020, , .		0
171	High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors. Journal of Neuro-Oncology, 2022, 158, 33-40.	2.9	0